Aciclovir (BW 248U)

Catalog No.S1807 Synonyms: Acyclovir, Acycloguanosine, Zovirax, ACV, NSC 645011

For research use only.

Acyclovir (BW 248U, Acyclovir, Acycloguanosine, Zovirax, ACV, NSC 645011) is a synthetic nucleoside analogue active against herpesviruses. Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells.

Aciclovir (BW 248U) Chemical Structure

CAS No. 59277-89-3

Selleck's Aciclovir (BW 248U) has been cited by 14 publications

Purity & Quality Control

Choose Selective Antiviral Inhibitors

Biological Activity

Description Acyclovir (BW 248U, Acyclovir, Acycloguanosine, Zovirax, ACV, NSC 645011) is a synthetic nucleoside analogue active against herpesviruses. Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells.
Targets
HSV [1]
In vitro

Acyclovir sensitivity of herpes simplex virus isolates is determined in a plaque-reduction assay in Vero cells. IC50 Values are consistently 2-3 fold lower in B2 compared with the H strain of Vero cells. HSV Type 2 strains are 2-10-fold less sensitive than Type 1 strains[2].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BSC-1 cells NHvpPVdHfW6ldHnvckBie3OjeR?= Mln4RY51cX[rcnHsJIFkfGm4aYT5JI9nKHSqZTDjc41xd3WwZDD3ZZMh\X[jbIXheIVlKGGpYXnud5QhfGinIFjldpBmeyC|aX3wcIV5KH[rcoXzJJR6eGVvMTDpckBDW0NvMTDj[YxteyxiSVO1NF0zNjZizszN MlGzNlkyOzNyMB?=
P3HR-1 cells NVLZSlZ2TnWwY4Tpc44h[XO|YYm= MVvF[oZm[3SrdnWgZ49v[2WwdILheIlwdiCob4KgeIhmKGmwaHnibZRqd25ib3[gSZB{fGWrbj3CZZJzKH[rcoXzJGVDXi2GTlGgd5lvfGinc3nzJIlvKGi3bXHuJIx6dXCqb3LsZZN1d2mmIGCzTHIuOSClZXzsd{whTUN3ME22Mlc2KM7:TR?= M4e0[VEzPDB6N{K2
HFF cells NV7EOnVxTnWwY4Tpc44h[XO|YYm= NVPYTVE3S2:wY3XueJJifGmxbjDmc5IhUFOYLUGgdIxieXWnIILl[JVkfGmxbjCoWnBTMSCkeTC1NEUhcW5iSF\GJINmdGy|LDDFR|UxRTFwMTFOwG0> NIHQTpUyPDV6NEm1OC=>
HFF cells NGjXVnNHfW6ldHnvckBie3OjeR?= MWfJcohq[mm2b4L5JINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gdoVlfWOnIFjTWk0yKGmwZIXj[YQh[3m2b4DheIhw\2WwaXOg[YZn\WO2IDjDVGUqKGK7IEWwJEUhcW5iSF\GJINmdGy|LDDFR|UxRTJwMkKg{txO NFvMR5cyPDV6NEm1OC=>
human embryonic lung cells NXX3emVKTnWwY4Tpc44h[XO|YYm= MnnSRY51cX[rcnHsJIFkfGm4aYT5JJdieyCvZXHzeZJm\CCjczDl[oZm[3SrdnWgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDy[YR2[2ViVnHybYNmdGyjIGrvd5RmeiC4aYL1d{ApV0uDKT3pcoR2[2WmIIDsZZF2\SCob4LtZZRqd25iaX6gbJVu[W5iZX3idplwdmmlIHz1coch[2WubIOsJGVEPTB;MT6xJO69VQ>? NH3vRYgyOTV2OUS1Oy=>
HEL cells NEXie|lHfW6ldHnvckBie3OjeR?= NGrsTHVEd22yb4Xu[EB4[XNidHXzeIVlKG[xcjDhcpRqNX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTHNXNTFqRzmgbY4hUEWOIHPlcIx{NCCHQ{WwQVEvOyEQvF2= M1S0dFE1PjR|M{K4
HEL cell NYnqUWVPTnWwY4Tpc44h[XO|YYm= M{Kzb2Vn\mWldHn2[UBkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgWJlzd3OrbnWgb4lv[XOnIDjUT{sqKF[jcnnj[Yxt[S2cb4P0[ZIhfmm{dYOtbY5lfWOnZDDjfZRweGG2aHnjbZR6KGK7IEWwKUBqdiCRS1Ggd5Rz[WmwIFjFUEBk\WyuIHzpcoV{NCCHQ{WwQVQvPTNizszN MmnCNVE1QTV3OE[=
HSV-2 MS Vero cells MmDUSpVv[3Srb36gZZN{[Xl? MYLJcohq[mm2aX;uJI9nKH[rcnHsJIN6fG:yYYTobYMh\W[oZXP0JIlvKGmwZnXjeIVlKGi3bXHuJIZwemW|a3nuJIZq[nKxYnzhd5Qh[2WubDDtc45wdGG7ZYLzJI9nKEiVVj2yJG1UKF[ncn:gZ4VtdHNiYomgOVAmNCCHQ{WwQVYvOiEQvF2= NVzQcnRmOTF3OEW0OVc>
HSV-1 E-377 Vero cells MULGeY5kfGmxbjDhd5NigQ>? MknlTY5pcWKrdHnvckBw\iCybHHxeYUh\m:{bXH0bY9vKGmwIH3vco9t[XmncoOgc4YhUFOYLUGgSU0{PzdiVnXyc{Bk\WyuczDifUA2OCVuIFXDOVA:PC52IN88US=> MXSxNVU5PTR3Nx?=
HSV-1 KOS Vero cells M{HYTWZ2dmO2aX;uJIF{e2G7 MojDTY5pcWKrdHnvckBw\iCybHHxeYUh\m:{bXH0bY9vKGmwIH3vco9t[XmncoOgc4YhUFOYLUGgT29UKF[ncn:gZ4VtdHNiYomgOVAmNCCHQ{WwQVIvOiEQvF2= MUWxNVU5PTR3Nx?=
HeLa cell NGTySmdHfW6ldHnvckBie3OjeR?= MXPBZoltcXS7IITvJIlvcGmkaYSgZ5l1d3CjdHjv[4VvcWOrdImgc4YhcGW{cHXzJJNqdXCuZYigeJlx\SBzII\pdpV{KCiJKTDpckBJ\UyjIHPlcIwh[3WudIXy[UwhUUN3ME2wMlE6KM7:TR?= M1nvc|EyOzV4MUGw
HEp-2 cells MoCzSpVv[3Srb36gZZN{[Xl? MXLNbY5qdXWvIHnubIljcXSxcomgZ49v[2WwdILheIlwdiClYYXzbY5oKDJ3JTDpcohq[mm2aX;uJI9nKGO7dH;wZZRpcWNiZX\m[YN1KGmwZIXj[YQh[nliSHXydIV{KHOrbYDs[Zghfmm{dYOtNUApUzl5OTmgbY4hUEWyLUKgZ4VtdHN? MWmyPFQzPTB4
HeLa cells Mmq5SpVv[3Srb36gZZN{[Xl? NX3qcVhYUW6qaXLpeIlwdiCxZjDIV3YuOSCGTlGgd5lvfGinc3nzJIlvKH[rcoXzMYlv\mWldHXkJGhmVGFiY3XscJMtKEmFNUC9NU46KM7:TR?= M3G5S|c4PTJ{ME[=
human HFF cells NYnYZ21tTnWwY4Tpc44h[XO|YYm= M{G1[2lvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDv[kB1cGViZIL1[{Bi\2GrboP0JJRp\SCleYTvdIF1cGmlIHXm[oVkfCCob4KgSU0{Pzdic4TyZYlvKG:oIHjldpBmeyC|aX3wcIV5KH[rcoXzMVEhMEiVVj2xLUBqdiCqdX3hckBJTkZiY3XscJMtKEWFNUC9NE4xPCEQvF2= M3HSfFg{QTR7M{O=
human HFF cells MVjGeY5kfGmxbjDhd5NigQ>? MnLJTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIH;mJJRp\SCmcoXnJIFo[Wmwc4SgeIhmKGO7dH;wZZRpcWNiZX\m[YN1KG[xcjDNV{B{fHKjaX6gc4YhcGW{cHXzJJNqdXCuZYigeolzfXNvMjCoTHNXNTJrIHnuJIh2dWGwIFjGSkBk\WyuczygSWM2OD1yLkC5JO69VQ>? MXO4N|k1QTN|
MRC-5 cells NEK5Uo9HfW6ldHnvckBie3OjeR?= M4DGbmFvfGm4aYLhcEBi[3Srdnn0fUBqdiCybHHxeYUhemWmdXP0bY9vKGG|c3H5JJdieyCmZYTldo1qdmWmIHHnZYlve3RiaHXydIV{KHOrbYDs[Zghfmm{dYOgeJlx\SB{IDjIV3YuOiliaX6gUXJENTViY3XscJMtKEmFNUC9Nk42KM7:TR?= M3HESFIyPTN{MEK=
human lung fibroblasts (MRC-5) NV7oOVFzTnWwY4Tpc44h[XO|YYm= Mm\BR49ueG:3bnSge4F{KHSnc4Tl[EBnd3JiYX70bZZqemGuIHHjeIl3cXS7IHHnZYlve3RiSHXydIV{KFOrbYDs[Zghfmm{dYOgWJlx\S1zKEG4NVg6MSCrbjDoeY1idiCudX7nJIZq[nKxYnzhd5R{KCiPUlOtOUk> NFz4PVI{ODRyOUm4
Raji cells NHHMVYZHfW6ldHnvckBie3OjeR?= M{i3NGlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDv[kB1cGViZIL1[{Bi\2GrboP0JJRp\SCjboTp[4VvKHC{b3T1Z5Rqd25iYXfhbY5{fCCSM1jSMVEhe3S{YXnuJI9nKGWyc4TlbY4h[mG{cjD2bZJ2ey1{IDjFRnYqKGmwIGLhbokh[2WubIOsJGVEPTB;Mj65JO69VQ>? MX64N|k1QTN|
Vero cells MYDGeY5kfGmxbjDhd5NigQ>? NIHUdnFKdmirYnn0c5J6KGGldHn2bZR6KGGpYXnud5QhcGW{cHXzJJNqdXCuZYigeolzfXNidInw[UAzKCiKU2[gNkkhe3S{YXnuJFE5PiCrbjDW[ZJwKGOnbHzzMEBKSzVyPUGuO{DPxE1? MnrvPFU4Pjl{Mh?=
BSC-1 cells MWHGeY5kfGmxbjDhd5NigQ>? M3T1NWVn\mWldHn2[UBkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgbIVzeGW|IIPpcZBt\XhidnnyeZMhOSCrbjDCV2MuOSClZXzsd{BqdiCHTFnTRUwhTUN3ME2xMlUh|ryP M3fvVVE2PjN2MECz
HFF cells MVnGeY5kfGmxbjDhd5NigQ>? MoO0SYZn\WO2aY\lJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDD2ZZJq[2WubHGgfo9{fGW{II\pdpV{KHKncHzpZ4F1cW:wIHnuJGhHTiClZXzsd{whTUN3ME2xMlYh|ryP NIDVd3QyPTZ|NECwNy=>
HFF cells Ml;sSpVv[3Srb36gZZN{[Xl? M4DNSmVn\mWldHn2[UBkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgbIVzeGW|IIPpcZBt\XhidnnyeZMhOSCrbjDISmYh[2WubIOgbY4h[3m2b4DheIhq[yCnZn\lZ5QhMEOSRTmgZZN{[XluIFXDOVA:OC57IN88US=> NFn3dJEyPTZ|NECwNy=>
Daudi cells NWG3OZAzTnWwY4Tpc44h[XO|YYm= MlKzTY5pcWKrdHnvckBw\iCHQm[gdoVxdGmlYYTpc44hcW5iRHH1[Ikh[2WubIOgZpkhfmm{YXygZ4Fxe2mmIHHueIlo\W5vRVzJV2EtKEWFNUC9NE4{OyEQvF2= M37LZlE4ODB2N{K2
african green monkey Vero cells Mnn4SpVv[3Srb36gZZN{[Xl? M4q4TlQ5KGh? MnmxRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTHNXOiC|dILhbY4hOzN|IHnu[oVkfGWmIHnuJIFnemmlYX6g[5Jm\W5ibX;ub4V6KF[ncn:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCleYTvdIF1cGmlIHXm[oVkfCCjZoTldkA1QCCqcoOgZpkheGyjcYXlJJJm\HWldHnvckBie3OjeTygSWM2OD1zLki3JO69VQ>? MkDaNlI4ODR6OUC=
WI-38 cell NWHwV4FlTnWwY4Tpc44h[XO|YYm= NG\m[mxCdnSrII\pdoFtKGGldHn2bZR6KGGpYXnud5QhXlqYKIDwcIxiKHO2cnHpckkhcW5iV1mtN|gh[2WubDDtc45wdGG7ZYLzMEBKTDVyPUSg{txO MoPhNVMyPjl4Nh?=
HEL cells M{nFW2Z2dmO2aX;uJIF{e2G7 MX20JIRigXN? M2rlcWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhUXjFiS1;TJIlv\mWldHXkJIlvKEiHTDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcoXzMYlv\HWlZXSgZ5l1d3CjdHjv[4VvcWOrdImgZYZ1\XJiNDDkZZl{NCCHQ{WwQVAvOiEQvF2= NELBZpEzOjR3OUi3Oi=>
HEL cells NWO3PWZZTnWwY4Tpc44h[XO|YYm= NHnLd41CdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJW1ZzIFvPV{Bqdm[nY4Tl[EBqdiCKRVygZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYL1d{1qdmS3Y3XkJIN6fG:yYYTobYMh\W[oZXP0MEBGSzVyPUCuNVQh|ryP NH3HUlEzOzB7OUC5Oy=>
African green monkey Vero 76 cells MoLBR5l1d3SxeHnjbZR6KGG|c3H5 M3zMblQ5NTl4IHi= MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBC\nKrY3HuJIdz\WWwIH3vcotmgSCYZYLvJFc3KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JJRwKDl4IHjyd{BjgSClconzeIFtKH[rb3zleEB{fGGrbnnu[{whS0N3ME2xN{DPxE1? MVGyOlEyQTl7Mh?=
In vivo low-dose oral acyclovir may be effective in the prevention of HSV infection during OKT3 treatment of seropositive patients. Continuation of acyclovir prophylaxis for two to four weeks following the conclusion of OKT3 therapy may prevent occurrence of delayed infections[3].

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 225.2
Formula

C8H11N5O3

CAS No. 59277-89-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=NC2=C(N1COCCO)N=C(NC2=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05468619 Not yet recruiting Drug: Valacyclovir Herpes Simplex National Institute of Allergy and Infectious Diseases (NIAID) September 9 2022 Phase 1
NCT05198570 Active not recruiting Other: Pharmacokinetic analysis Herpesviridae Infections|Herpes Simplex 1|Varicella Zoster Virus Infection|Transplantation Infection|Oncology University of Pisa|IRCCS Burlo Garofolo September 15 2021 --
NCT04448392 Recruiting Drug: Valacyclovir Neonatal Herpes Simplex Infection University of Alabama at Birmingham July 1 2021 Phase 1
NCT02997982 Completed Drug: Valaciclovir 500Mg Tablet Alzheimer Disease|Mild Cognitive Impairment|Herpes Simplex Hugo Lovheim|Umeå University December 2016 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Aciclovir (BW 248U) | Aciclovir (BW 248U) ic50 | Aciclovir (BW 248U) price | Aciclovir (BW 248U) cost | Aciclovir (BW 248U) solubility dmso | Aciclovir (BW 248U) purchase | Aciclovir (BW 248U) manufacturer | Aciclovir (BW 248U) research buy | Aciclovir (BW 248U) order | Aciclovir (BW 248U) mouse | Aciclovir (BW 248U) chemical structure | Aciclovir (BW 248U) mw | Aciclovir (BW 248U) molecular weight | Aciclovir (BW 248U) datasheet | Aciclovir (BW 248U) supplier | Aciclovir (BW 248U) in vitro | Aciclovir (BW 248U) cell line | Aciclovir (BW 248U) concentration | Aciclovir (BW 248U) nmr